FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The accelerated approval is supported by results from part 1 of the ESSENCE trial
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Vasograin Plus represents a major advancement in the treatment of migraine
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Subscribe To Our Newsletter & Stay Updated